|
MechanismKATP channels activators |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date21 Sep 1983 |
盐酸氟桂利嗪胶囊(5mg)随机、开放、两周期、两交叉健康人体空腹和餐后状态下生物等效性试验
[Translation] Bioequivalence trial of flunarizine hydrochloride capsules (5mg) in a randomized, open-label, two-cycle, two-crossover healthy human subjects in fasting and postprandial states
研究健康受试者在空腹及餐后状态下,单次口服由江苏平光制药(焦作)有限公司生产的盐酸氟桂利嗪胶囊(受试制剂,5mg/粒)和西安杨森制药有限公司生产的盐酸氟桂利嗪胶囊(参比制剂,5mg/粒,商品名: SIBELIUM西比灵)的相对生物利用度,评价受试制剂与参比制剂间的生物等效性,并为受试制剂的工艺优化和临床用药提供依据。
[Translation] Study healthy subjects took a single oral dose of flunarizine hydrochloride capsules (test preparation, 5mg/capsule) produced by Jiangsu Pingguang Pharmaceutical (Jiaozuo) Co., Ltd. and Xi'an Janssen Pharmaceutical Co., Ltd. The relative bioavailability of flunarizine hydrochloride capsules (reference preparation, 5mg/capsule, trade name: SIBELIUM), the bioequivalence between the test preparation and the reference preparation was evaluated, and it was the same as the test preparation. Provide the basis for process optimization and clinical medication.
100 Clinical Results associated with Jiangsu Pingguang Pharmaceutical (Jiaozuo) Co., Ltd.
0 Patents (Medical) associated with Jiangsu Pingguang Pharmaceutical (Jiaozuo) Co., Ltd.
100 Deals associated with Jiangsu Pingguang Pharmaceutical (Jiaozuo) Co., Ltd.
100 Translational Medicine associated with Jiangsu Pingguang Pharmaceutical (Jiaozuo) Co., Ltd.